This archive contains the following articles listed by volume, issue and page number:
 |
|
|
| Volume 18, 2014 Articles |
| Title (Click for Details) |
Vol/Issue |
Page |
| PreScription: The International Journal of Pharmaceutical Compounding Begins Its 18th Year |
Vol. 18 No. 1 |
4 |
| The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013 |
Vol. 18 No. 1 |
6 |
| Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report |
Vol. 18 No. 1 |
14 |
| Good Enough for America |
Vol. 18 No. 1 |
20 |
| Determination of Risk for Sterile Preparations |
Vol. 18 No. 1 |
30 |
| U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 |
Vol. 18 No. 1 |
35 |
| Marketing |
Vol. 18 No. 1 |
38 |
| Tips and Hints: Powders, Capsules, Tablets, Suppositories, and Sticks |
Vol. 18 No. 1 |
42 |
| Quality Control Analytical Methods: Laboratory Considerations of United States Pharmacopeia Chapter <71> Sterile Tests and Its Application to Pharmaceutical Compounding |
Vol. 18 No. 1 |
46 |
| Basics of Sterile Compounding: Bubble Point Testing |
Vol. 18 No. 1 |
54 |
| Calculations |
Vol. 18 No. 1 |
58 |
| Aztreonam Injection |
Vol. 18 No. 1 |
60 |
| Bumetanide 0.25-mg/mL Injection |
Vol. 18 No. 1 |
61 |
| Droperidol 2.5-mg/mL Injection |
Vol. 18 No. 1 |
62 |
| Lomustine 100-mg Capsules |
Vol. 18 No. 1 |
63 |
| Neostigmine Bromide 15-mg Capsules |
Vol. 18 No. 1 |
64 |
| Nimodipine 30-mg Capsules |
Vol. 18 No. 1 |
65 |
| Phenobarbital 60-mg Capsules |
Vol. 18 No. 1 |
66 |
| Potassium Chloride 2-mEq/mL Injection |
Vol. 18 No. 1 |
67 |
| Procainamide Hydrochloride 100-mg/mL Injection |
Vol. 18 No. 1 |
68 |
| Vasopressin 20-units/mL Injection |
Vol. 18 No. 1 |
69 |
| The Effectiveness of Sublingual and Topical Compounded Bioidentical Hormone Replacement Therapy in Post-menopausal Women: An Observational Cohort Study |
Vol. 18 No. 1 |
70 |
| Long-term Stability of Morphine Hydrochloride in 0.9% NaCl Infusion Polyolefin Bags After Freeze-thaw Treatment and in Polypropylene Syringes at 5°C ± 3°C |
Vol. 18 No. 1 |
78 |
| E-Prescribing Errors Identified in a Compounding Pharmacy: A Quality-improvement Project |
Vol. 18 No. 1 |
83 |
| PostScription: Pharmacy Benefit Managers and Compounding Pharmacists: Billing for Services |
Vol. 18 No. 1 |
87 |
| PreScription: Standards vs Opinions |
Vol. 18 No. 2 |
92 |
| A Needle-free Reconstitution and Transfer System for Compounded Sterile Intravenous Drug Solutions: In Compliance with United States Pharmacopeia Chapter <797> Standards |
Vol. 18 No. 2 |
94 |
| Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective |
Vol. 18 No. 2 |
101 |
| Compounding Practices in Iran |
Vol. 18 No. 2 |
112 |
| IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities |
Vol. 18 No. 2 |
117 |
| Effective Advertisements |
Vol. 18 No. 2 |
120 |
| Quality Control Analytical Methods: The Essentials of United States Pharmacopeia Chapter <51> Antimicrobial Effectiveness Testing and Its Application in Pharmaceutical Compounding |
Vol. 18 No. 2 |
123 |
| Basics of Sterile Compounding: Compounding by Weight Versus Compounding by Volume |
Vol. 18 No. 2 |
131 |
| Basics of Compounding: Tips and Hints, Part 2: Compounding with Solutions, Suspensions, Emulsions, and Lotions |
Vol. 18 No. 2 |
137 |
| Calculations |
Vol. 18 No. 2 |
140 |
| Doxazosin 1-mg, 2-mg, 4-mg, or 8-mg Capsules |
Vol. 18 No. 2 |
142 |
| Fludarabine Phosphate 25-mg/mL Injection |
Vol. 18 No. 2 |
143 |
| Mecasermin 10-mg/mL Injection |
Vol. 18 No. 2 |
144 |
| Methylprednisolone 40-mg/mL Injection |
Vol. 18 No. 2 |
145 |
| Polymixin B Injection |
Vol. 18 No. 2 |
146 |
| Rocuronium Bromide 10-mg/mL Injection |
Vol. 18 No. 2 |
147 |
| Secretin 4 mcg/mL Injection |
Vol. 18 No. 2 |
148 |
| Selenium 40-mcg/mL Injection |
Vol. 18 No. 2 |
149 |
| Sincalide 1-mcg/mL Injection |
Vol. 18 No. 2 |
150 |
| Testosterone Enanthate 200-mg/mL Injection |
Vol. 18 No. 2 |
151 |
| Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride |
Vol. 18 No. 2 |
152 |
| E-Prescription Errors and Their Resolution in a Community Compounding Pharmacy |
Vol. 18 No. 2 |
159 |
| The Standardization of Nonsterile Compounding: A Study in Quality Control and Assessment for Hormone Compounding |
Vol. 18 No. 2 |
162 |
| Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets |
Vol. 18 No. 2 |
169 |
| Recharting Your Vision While Remaining True to Your Charter |
Vol. 18 No. 2 |
175 |
| PreScription: Déjà Vu All Over Again |
Vol. 18 No. 3 |
180 |
| A Brief Survey on Prescriber Beliefs Regarding Compounded Topical Pain Medications |
Vol. 18 No. 3 |
182 |
| Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice |
Vol. 18 No. 3 |
190 |
| Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation |
Vol. 18 No. 3 |
203 |
| The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter |
Vol. 18 No. 3 |
208 |
| Marketing: Effective Use of Advertisements on Your Website |
Vol. 18 No. 3 |
210 |
| Quality Control Analytical Methods: Microbial Limit Tests for Nonsterile Pharmaceuticals, Part 1 |
Vol. 18 No. 3 |
213 |
| Quality Control Analytical Methods: Establishing Powder-handling Workflow Practices and Standard Operating Procedures: Compounding Pharmacy and Safety |
Vol. 18 No. 3 |
222 |
| Basics of Compounding: Tips and Hints, Part 3: Compounding with Ointments, Creams, Pastes, Gels, and Gel-creams |
Vol. 18 No. 3 |
228 |
| Calculations |
Vol. 18 No. 3 |
231 |
| Atorvastatin 10-mg or 20-mg Capsules |
Vol. 18 No. 3 |
232 |
| Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules |
Vol. 18 No. 3 |
233 |
| Bupivacaine Hydrochloride 0.5% Injection |
Vol. 18 No. 3 |
234 |
| Butorphanol Tartrate 10-mg/mL Nasal Spray |
Vol. 18 No. 3 |
235 |
| Dibucaine 1% Ointment |
Vol. 18 No. 3 |
236 |
| Lidocaine Hydrochloride 1% Injection |
Vol. 18 No. 3 |
237 |
| Methotrexate 2.5-mg Capsules |
Vol. 18 No. 3 |
238 |
| Naproxen 25-mg/mL Oral Suspension |
Vol. 18 No. 3 |
239 |
| Tamoxifen 10-mg or 20-mg Capsules |
Vol. 18 No. 3 |
240 |
| Thiothixene 1-mg, 2-mg, 5-mg, or 10-mg Capsules |
Vol. 18 No. 3 |
241 |
| Examination of the Order of Incubation for the Recovery of Bacteria and Fungi from Pharmaceutical-grade Cleanrooms |
Vol. 18 No. 3 |
242 |
| Investigation of Physical and Chemical Stability of an Ointment with Herbals |
Vol. 18 No. 3 |
248 |
| Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date |
Vol. 18 No. 3 |
253 |
| Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery |
Vol. 18 No. 3 |
256 |
| PostScription: The Fourth Annual Student Pharmacist Compounding Competition: Building Future Leaders in the Industry |
Vol. 18 No. 3 |
262 |
| PreScription: Challenging Times |
Vol. 18 No. 4 |
268 |
| Vial Washers for the Compounding Pharmacy: Ensuring Preparation Safety |
Vol. 18 No. 4 |
270 |
| Compounded Pain Formulations: What is the Evidence? |
Vol. 18 No. 4 |
278 |
| Oral Mucosal Immunotherapy Using a Toothpaste Delivery System for the Treatment of Allergic Rhinitis |
Vol. 18 No. 4 |
287 |
| Color Additives: Legislative Perspective in the United States, Europe, Australia, and India |
Vol. 18 No. 4 |
293 |
| 400 Attendees Convene in Washington, D.C., for the 20th Annual Compounders on Capitol Hill |
Vol. 18 No. 4 |
302 |
| Quality Control: Microbial Limit Tests for Nonsterile Pharmaceuticals, Part 2 |
Vol. 18 No. 4 |
305 |
| Basics of Compounding Sterile Preparations: Nomenclature and Considerations |
Vol. 18 No. 4 |
313 |
| Basics of Compounding: Tips and Hints, Part 4: Lollipops/Lozenges, Gummy Bears, Patches, Flavoring/Coloring, Sweeteners, and Packaging |
Vol. 18 No. 4 |
318 |
| Calculations |
Vol. 18 No. 4 |
320 |
| Atracurium Besylate 10-mg/mL Injection, Preserved |
Vol. 18 No. 4 |
322 |
| Barium Sulfate Suspension |
Vol. 18 No. 4 |
323 |
| Calcitriol 1-mcg/mL Injection |
Vol. 18 No. 4 |
324 |
| Chloramphenicol 100-mg/mL Injection |
Vol. 18 No. 4 |
325 |
| Chlorothiazide 50-mg/mL Oral Suspension |
Vol. 18 No. 4 |
326 |
| Choline Magnesium Trisalicylate Liquid |
Vol. 18 No. 4 |
327 |
| Denileukin Diftitox 150-mcg/mL Injection |
Vol. 18 No. 4 |
328 |
| Indigo Carmine Injection |
Vol. 18 No. 4 |
329 |
| Propranolol Hydrochloride 1-mg/mL Injection |
Vol. 18 No. 4 |
330 |
| Zinc 1-mg/mL Injection |
Vol. 18 No. 4 |
331 |
| Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream |
Vol. 18 No. 4 |
332 |
| Assessing the Use of Food Coloring as an Appropriate Visual Guide for Homogenously Mixed Capsule Powders in Extemporaneous Compounding |
Vol. 18 No. 4 |
341 |
| Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date |
Vol. 18 No. 4 |
345 |
| Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date |
Vol. 18 No. 4 |
348 |
| PostScription: Responsibilities of a Compounding Pharmacist |
Vol. 18 No. 4 |
351 |
| PreScription: What is a Compounding Pharmacist? |
Vol. 18 No. 5 |
356 |
| Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy |
Vol. 18 No. 5 |
358 |
| To Compound or Not to Compound: A Veterinary Transdermal Discussion |
Vol. 18 No. 5 |
366 |
| Autologous Serum Eye Drops for Severe Dry Eye Syndrome in a Patient with Chronic Graft-vs-Host Disease: A Case Report |
Vol. 18 No. 5 |
370 |
| Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A |
Vol. 18 No. 5 |
379 |
| Health Care in Belarus in the 19th and 20th Centuries |
Vol. 18 No. 5 |
382 |
| Compounding Practices in a Portuguese Community Pharmacy |
Vol. 18 No. 5 |
392 |
| Basics of Compounding: Certification of Sterile Equipment and Facilities: What Pharmacists Need to Know |
Vol. 18 No. 5 |
397 |
| Basics of Compounding: Tips and Hints, Part 5: Facilities and Equipment |
Vol. 18 No. 5 |
401 |
| Marketing: Tips on Dealing With a Healthcare Practititioner's No-Rep Policy |
Vol. 18 No. 5 |
406 |
| Calculations |
Vol. 18 No. 5 |
407 |
| Azithromycin 100-mg/mL Injection |
Vol. 18 No. 5 |
408 |
| Bacitracin Topical Ointment |
Vol. 18 No. 5 |
409 |
| Dexpanthenol 250-mg/mL Injection |
Vol. 18 No. 5 |
410 |
| Ephedrine Sulfate 50-mg/mL Injection |
Vol. 18 No. 5 |
411 |
| Fluorescein 100-mg/mL Injection |
Vol. 18 No. 5 |
412 |
| Indocyanine green 2.5-mg/mL Injection |
Vol. 18 No. 5 |
413 |
| Phenylephrine Hydrochloride 2.5%-Ophthalmic Solution |
Vol. 18 No. 5 |
414 |
| Sulfamethoxazole and Trimethoprim Oral Solution |
Vol. 18 No. 5 |
415 |
| Sumatriptan Succinate 12-mg/mL Injection |
Vol. 18 No. 5 |
416 |
| Tranexamic Acid 100-mg/mL Injection |
Vol. 18 No. 5 |
417 |
| Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation |
Vol. 18 No. 5 |
418 |
| Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition |
Vol. 18 No. 5 |
427 |
| Stability of Tranexamic Acid in 0.9% Sodium Chloride, Stored in Type 1 Glass Vials and Ethylene/Propylene Copolymer Plastic Containers |
Vol. 18 No. 5 |
432 |
| PostScription: The Future of Veterinary Compounding |
Vol. 18 No. 5 |
438 |
| PreScription: "Named Formulas" Database Available |
Vol. 18 No. 6 |
444 |
| Depyrogenation Options for the Compounding Cleanroom |
Vol. 18 No. 6 |
446 |
| Standards of Practice, Professional Judgment, and Scientific Evidence to Establish and Extend a Beyond-Use Date |
Vol. 18 No. 6 |
456 |
| Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Medications in a Rural Setting: A Case Study from the Delmarva Peninsula |
Vol. 18 No. 6 |
462 |
| Compounding Legislation: Focus Shifts to States |
Vol. 18 No. 6 |
470 |
| Quality Control: Can Compounding Pharmacy Learn from the Automotive Industry? |
Vol. 18 No. 6 |
475 |
| Basics of Compounding: Unique and Special Characteristics of Sterile Dosage Forms |
Vol. 18 No. 6 |
479 |
| Basics of Compounding: Tips and Hints, Part 6: Prescription Evaluation, Calculations, Ingredients, Quality-Assurance Practices, Patient Counseling, Shipping and Distribution, Miscellaneous |
Vol. 18 No. 6 |
486 |
| Marketing: Using Facebook to Market Your Compounding Pharmacy |
Vol. 18 No. 6 |
490 |
| Calculations |
Vol. 18 No. 6 |
492 |
| Clarithromycin 250-mg or 500-mg Capsules |
Vol. 18 No. 6 |
494 |
| Dexmedetomidine 100 mcg/mL Injection |
Vol. 18 No. 6 |
495 |
| Dexmethylphenidate Hydrochloride 2.5-mg, 5-mg, or 10-mg Capsules |
Vol. 18 No. 6 |
496 |
| Leucovorin 10-mg/mL Injection |
Vol. 18 No. 6 |
497 |
| Levocarnitine 200-mg/mL Injection |
Vol. 18 No. 6 |
498 |
| Methazolamide 25-mg or 50-mg Capsules |
Vol. 18 No. 6 |
499 |
| Methylene Blue 10-mg/mL Injection |
Vol. 18 No. 6 |
500 |
| Methylphenidate Hydrochloride 10-mg Capsules |
Vol. 18 No. 6 |
501 |
| Oxacillin Sodium 167-mg/mL Injection |
Vol. 18 No. 6 |
502 |
| Tamsulosin Hydrochloride 0.2-mg Capsules |
Vol. 18 No. 6 |
503 |
| Skin Penetration and Antinociception of Topical Gabapentin Formulations |
Vol. 18 No. 6 |
504 |
| In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations |
Vol. 18 No. 6 |
512 |
| Effect of Emulsifier Pairs on Physical Stability of Emulsions Containing Three Different Natural Oils |
Vol. 18 No. 6 |
516 |
| High-Performance Liquid Chromatographic Method Optimization for Ondansetron Assay in Extemporaneous Topical Gel and in Marketed Products |
Vol. 18 No. 6 |
520 |
| PostScription: Pharmacy Compounding Accreditation Board: Past, Present, and Future |
Vol. 18 No. 6 |
526 |
